(19)
(11) EP 4 583 922 A2

(12)

(88) Date of publication A3:
11.04.2024

(43) Date of publication:
16.07.2025 Bulletin 2025/29

(21) Application number: 23863945.4

(22) Date of filing: 06.09.2023
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61K 47/64(2017.01)
C07K 16/36(2006.01)
A61K 47/54(2017.01)
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/6849; A61K 47/6889; A61K 47/68037; C07K 16/36
(86) International application number:
PCT/US2023/073516
(87) International publication number:
WO 2024/054821 (14.03.2024 Gazette 2024/11)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 07.09.2022 US 202263404447 P
25.04.2023 US 202363498233 P

(71) Applicant: Exelixis, Inc.
Alameda, CA 94502 (US)

(72) Inventors:
  • BARFIELD, Robyn, M.
    Alameda, CA 94502 (US)
  • BAUZON, Maxine
    Alameda, CA 94502 (US)
  • DRAKE, Penelope, M.
    Alameda, CA 94502 (US)
  • KANTAK, Seema
    Alameda, CA 94502 (US)
  • MENDELSOHN, Brian, Alan
    Alameda, CA 94502 (US)
  • UNSULANGI, Tiffany
    Alameda, CA 94502 (US)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Gewürzmühlstraße 11
80538 München
80538 München (DE)

   


(54) TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND USES THEREOF